iNtRON Biotechnology, Inc. (KOSDAQ:048530)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,625.00
-55.00 (-1.18%)
Mar 12, 2026, 3:30 PM KST
Market Cap143.46B -15.4%
Revenue (ttm)5.56B -35.5%
Net Income-6.29B
EPS-197.47
Shares Out30.65M
PE Ration/a
Forward PEn/a
Dividend100.00 (2.14%)
Ex-Dividend DateDec 29, 2025
Volume1,868,214
Average Volume3,194,235
Open4,790.00
Previous Close4,680.00
Day's Range4,495.00 - 5,130.00
52-Week Range2,895.00 - 7,010.00
Beta0.30
RSI51.24
Earnings DateMar 13, 2026

About iNtRON Biotechnology

iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 73
Stock Exchange KOSDAQ
Ticker Symbol 048530
Full Company Profile

Financial Performance

In 2024, iNtRON Biotechnology's revenue was 6.42 billion, a decrease of -33.05% compared to the previous year's 9.59 billion. Losses were -2.59 billion, -73.27% less than in 2023.

Financial Statements